Linked Life Data

12848736

Source:http://linkedlifedata.com/resource/pubmed/id/12848736

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2003-7-9
pubmed:abstractText
In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated from serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. lwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1198-743X
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
563-7
pubmed:dateRevised
2006-11-7
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.
pubmed:affiliation
Antibiotic Development and Technical Support Group, AstraZeneca, Alderley House, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK. philip.turner@astrazeneca.com
pubmed:publicationType
Journal Article